Please tell us about your clinical experience. How many patients with Waldenstrom’s Macroglobulinemia do you see on a yearly basis? What % of patients experience remission?

How efficient is CLR 131 proving to be, as a small-molecule PDC in providing targeted delivery of iodine-131 directly to cancer cells, and also limiting exposure to healthy cells?

Could you please discuss the Phase 2 CLOVER-1 data where six WM patients demonstrated 100% overall response rate and an 83.3% major response rate with one patient achieving a CR of 27 months post- last treatment, in patients having received first line standard of care and failed treatment with BTK inhibitors? How often have second- and third-line patients reported a CR?

The company reports the average treatment free survival is currently at 330 days. Is this result in line with clinicians' expectations?

Are there any parallels that can be drawn from looking at the 131-I-MIBG data in pediatric oncology? Company cites that although CLR 131 differs from 131-I-MIBG in some of the drug properties, the active moiety, 131-I is identical.

Can you give us your high level thoughts on the complete, updated Phase 2 data, where:-Median time to initial response was 22 days after first infusion-Median time to major response, as defined as at least a 50% reduction in IgM, was 44 days after first infusion-Mean treatment free remission, as defined as the time from the last CLR 131 infusion to progression of disease, is 1.1 years and remains ongoing-Duration of response has not been reached, with 100% of the MYD88 wild type and high risk patients exceeding 8.5 months-Progression free survival (PFS) for both MYD88 wild type patients as well as the high-risk subgroup has not been reached after 18 months; PFS for multidrug refractory patients was 11 months-The most frequently reported treatment emergent adverse events were cytopenias

How likely would you be to treat patients with CLR 131?